Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Dr. Reddy's Laboratories gains on launching Bupropion HCI Tablets in US market

06-Sep2016

Dr. Reddy's Laboratories gains on launching Bupropion HCI Tablets in US market

Dr. Reddy's Laboratories is currently trading at Rs. 3137.05, up by 14.40 points or 0.46% from its previous closing of Rs. 3122.65 on the BSE.

The scrip opened at Rs. 3123.00 and has touched a high and low of Rs. 3142.85 and Rs. 3123.00 respectively.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.

Last one week high and low of the scrip stood at Rs. 3142.85 and Rs. 3019.00 respectively. The current market cap of the company is Rs. 51,959.00 crore.

The promoters holding in the company stood at 26.37%, while Institutions and Non-Institutions held 41.16% and 15.64% respectively.

Dr. Reddy's Laboratories has launched Bupropion HCI extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin SR (bupropion HCI) Sustained-Release Tablets in the United States market approved by the US Food & Drug Administration (USFDA). Dr. Reddy's Buproprion SR tablets are available in 100 mg, 150 mg and 200 mg, in bottle count sizes of 60, 100 and 500.

Wellbutrin SR is a registered trademark of the GSK group of companies. The Wellbutrin SR brand and generic had US sales of approximately $109.6 million MAT for the most recent twelve months ending in July 2016, according to IMS Health.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It is committed to provide affordable and innovative medicines for healthier lives.  It manufactures and markets a wide range of pharmaceuticals in India and overseas.



Related News

View all news

IndusInd Bank surges on reporting 5% rise in Q2 net profit

IndusInd Bank is currently trading at Rs. 1663.60, up by 36.75 points or 2.26% from its previous closing of Rs. 1626.85 on the BSE.The scrip opened at Rs. 1638.00 and has touched a high and low of Rs.......

Lupin rises with arm partnering with ASHA, NPWH

Lupin is currently trading at Rs. 897.00, up by 16.55 points or 1.88% from its previous closing of Rs. 880.45 on the BSE.The scrip opened at Rs. 889.80 and has touched a high and low of Rs. 910.00 and......

Alembic Pharma surges with receiving USFDA's tentative approval for Alogliptin Tablet

Alembic Pharmaceuticals is currently trading at Rs. 602.35, up by 6.50 points or 1.09% from its previous closing of Rs. 595.85 on the BSE.The scrip opened at Rs. 596.65 and has touched a high and low of......

Top News

View all news

Shalimar Paints lays down foundation of Nashik manufacturing plant

Shalimar Paints has laid down the foundation of a manufacturing unit to be rebuilt in Nashik, in the state of Maharashtra. The company set to commence operations by April 2019 with a planned production......

Delta Corp reports 11% rise in Q2 consolidated net profit

Delta Corp has reported results for second quarter ended September 30, 2018.The company has reported over 2-fold jump in its net profit at Rs 63.51 crore for the quarter under review as compared to Rs......

PNB plans to sell non-core assets worth Rs 8,600 crore during FY19

Punjab National Bank (PNB) has recognized various assets, including its housing finance arm, for sale and hopes to realise Rs 8,600 crore from these non-core assets during the current fiscal. Meanwhile,......